secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2026-05-14T20:23:47+00:00
Accession:  0001437749-26-017070
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3
-------------------------------------------------------------------

- Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).
- Cash $1.3M at March 31, 2026, down from $3.1M at Dec 31, 2025.
- Phase 3 immunobridging study for GEO-MVA (mpox/smallpox) planned under EMA-aligned expedited pathway; enrollment ~500.
- Completed cGMP manufacturing and fill/finish; CRO selected for trial initiation.
- Exclusive license from Emory for Gedeptin in combination with immune checkpoint inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/0001437749-26-017070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/govx20260513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer